公开(公告)号：EP4431493A1

公开(公告)日：2024-09-18

申请号：EP22894817.0

申请日：2022-11-16

申请人： Shenzhen Bay Laboratory ,  Peking University Shenzhen Graduate School

发明人： ZHU, Zhendong ,  XU, Zhengshuang ,  LI, Ting ,  CHE, Chao ,  REN, Xingye ,  CHEN, Sigui ,  ZHANG, Jiayin ,  ZHANG, Ben ,  YANG, Qi ,  ZHANG, Chuanbing ,  YANG, Zhen

IPC分类号： C07D205/04 ,  C07D213/30 ,  C07D401/02 ,  C07D401/14 ,  C07D409/02 ,  C07D403/14 ,  C07C65/26 ,  C07C63/49 ,  A61K31/44 ,  A61K31/4025 ,  A61K31/397 ,  A61K31/404 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P31/22

CPC分类号： A61K31/397 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/506 ,  A61P19/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P39/00 ,  C07C63/49 ,  C07C65/26 ,  C07D205/04 ,  C07D213/30 ,  C07D213/56 ,  C07D213/75 ,  C07D401/02 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D409/02 ,  C07D409/14 ,  C07D417/14

摘要： A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis, especially nasopharyngeal carcinoma. The present invention further provides a small molecule inhibitor against nasopharyngeal carcinoma, and/or a pharmaceutical composition comprising same, capable of being used for treating nasopharyngeal carcinoma.

公开(公告)号：EP4151621A1

公开(公告)日：2023-03-22

申请号：EP21817699.8

申请日：2021-05-31

申请人： Shenzhen Bay Laboratory ,  Peking University Shenzhen Graduate School

发明人： ZHU, Zhendong ,  XU, Zhengshuang ,  LI, Ting ,  CHE, Chao ,  ZHANG, Qingzhou ,  CHEN, Sigui ,  CHEN, Huangcan ,  XIANG, Dehu ,  YANG, Zhen

IPC分类号： C07C229/56 ,  C07C311/16 ,  C07C255/55

摘要： The present invention provides a small-molecule inhibitor targeting an EB virus nuclear antigen protein, and/or a pharmaceutical composition containing the same, which can be used for the treatment of a disease caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides a small-molecule inhibitor targeting an EB virus nuclear antigen protein, and/or a pharmaceutical composition containing the same, which can be used for the treatment of a disease caused by EBV infection in a lytic and/or latent phase.

公开(公告)号：EP4410301A1

公开(公告)日：2024-08-07

申请号：EP21958636.9

申请日：2021-09-28

申请人： Peking University Shenzhen Graduate School

发明人： QUAN, Junmin ,  YANG, Zhen ,  LIU, Siyu ,  ZHANG, Qingzhou ,  HU, Minqiang ,  LI, Fengxia ,  FU, Jiamiao ,  ZHU, Zhendong ,  LI, Qinkai

IPC分类号： A61K38/13 ,  A61K47/54 ,  A61P3/10 ,  A61P9/10 ,  A61P35/00

CPC分类号： A61P3/10 ,  A61K47/54 ,  A61K38/13 ,  A61P9/10 ,  A61P35/00

摘要： The present invention belongs to the technical field of biomedicine, and specifically relates to an extracellular cyclophilin inhibitor and the use thereof, wherein the structural general formula of the extracellular cyclophilin inhibitor of the present invention is as shown in formula (I). According to the present invention, a group capable of reacting with sulfhydryl of cysteine at a specific site on blood albumin is extracted by means of a side chain of a new cyclosporin derivative, and a drug conjugate is rapidly formed after same enters the body, which can effectively restrict the drug to the extracellular area and form targeted inhibition of extracellular cyclophilin, thereby achieving the aim of treating diseases associated therewith.